Document is current
Any future updates will be listed below
-
Authors
Datlinger, Paul https://orcid.org/0000-0001-7965-2543
Pankevich, Eugenia V. https://orcid.org/0000-0003-2030-387X
Arnold, Cosmas D. https://orcid.org/0009-0001-1850-4245
Pranckevicius, Nicole
Lin, Jenny
Romanovskaia, Daria https://orcid.org/0000-0003-2831-0919
Schaefer, Moritz https://orcid.org/0000-0001-6489-1947
Piras, Francesco
Orts, Anne-Christine
Nemc, Amelie
Biesaga, Paulina N.
Chan, Michelle
Neuwirth, Teresa
Artemov, Artem V.
Li, Wentao
Ladstätter, Sabrina https://orcid.org/0000-0001-5773-5436
Krausgruber, Thomas https://orcid.org/0000-0002-1374-0329
Bock, Christoph https://orcid.org/0000-0001-6091-3088
- License Information
-
More Information
Article History
Received: 22 September 2024
Accepted: 8 August 2025
First Online: 24 September 2025
Competing interests
: P.D., E.V.P. and C.B. are inventors on patent applications related to the CELLFIE platform and boosters of immunotherapy. C.B. is a cofounder of and scientific advisor to Myllia Biotechnology and Neurolentech. P.D. is a shareholder in Xaira Therapeutics through employee stock options. The remaining authors declare no competing interests.
